NCT07014059 is a Phase 2 clinical trial of Autologous Serum 20% in GVHD, sponsored by GIANCARLO FATOBENE.

Who is sponsoring NCT07014059?

NCT07014059 is sponsored by GIANCARLO FATOBENE.

What drugs are being tested in NCT07014059?

Interventions in NCT07014059: Autologous Serum 20%.

What condition does NCT07014059 study?

NCT07014059 studies GVHD, Meibomian Gland Dysfunction (Disorder), Stevens-Johnson Syndrome, Limbal Keratoconjunctivitis, Recurrent Erosions of Persistent Epithelial Defects, Neurotrophic Ulcer, Sjogren Syndrome With Keratoconjunctivitis.

Is NCT07014059 still recruiting?

NCT07014059 is currently not yet recruiting. Last updated 10 June 2025.

Last reviewed 2025-06-10 · How we verify

NCT07014059

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous Serum Obtained by a Closed-Circuit Collection Device

Not yet recruiting Phase 2 Last updated 10 June 2025

What this trial tests

Phase 2 trial testing Autologous Serum 20% in GVHD in 16 participants. Not yet recruiting.

Timeline

20 June 2025

Primary endpoint
20 June 2026

20 June 2027

Quick facts

Lead sponsor	GIANCARLO FATOBENE
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	20 June 2025
Primary completion	20 June 2026
Estimated completion	20 June 2027
Sites	1 location across Brazil

Drugs / interventions tested

Autologous Serum 20% — full drug profile →

Conditions studied

GVHD — all drugs for GVHD →
Meibomian Gland Dysfunction (Disorder) — all drugs for Meibomian Gland Dysfunction (Disorder) →
Stevens-Johnson Syndrome — all drugs for Stevens-Johnson Syndrome →
Limbal Keratoconjunctivitis — all drugs for Limbal Keratoconjunctivitis →

Sponsor

GIANCARLO FATOBENE

Who can join

18 and older, any sex, with GVHD or Meibomian Gland Dysfunction (Disorder). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Autologous serum eye drops (ASED) are an established therapy for ocular surface diseases; however, their preparation can be costly and may not be available due to the need for germ-free conditions. This pilot trial assesses the feasibility of collecting ASED in a closed-circuit system for patients with chronic ocular surface diseases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Autologous Serum 20%

Trials testing the same drug.

NCT03436576 — Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye · Phase 3 · unknown

Other recruiting trials for GVHD

Currently open trials in the same condition.

NCT06590285 — Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation · NA · recruiting
NCT05675930 — A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transpl · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07014059 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GIANCARLO FATOBENE
Last refreshed: 10 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07014059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing